Medicaid Pharmacy and Therapeutics Committee

New York State Office Of Medicaid Management
Pharmacy and Therapeutics Committee - Agenda for May 5, 2006

The Pharmacy & Therapeutics Committee will meet Friday, May 5, 2006, from 8:45 a.m. to 3:00 p.m., Meeting Room 6, Concourse, Empire State Plaza, Albany, New York

Agenda Items:

1. Proposal: Identification of preferred drugs in the therapeutic class Long Acting Narcotics.

  • Description: The Committee will review the following drugs to determine preferred and non-preferred status.

    Drugs Affected: Avinza (morphine sulfate ER), Duragesic (fentanyl), fentanyl, Kadian (morphine sulfate SR), morphine sulfate SR, MS Contin (morphine sulfate CR), Oramorph SR (morphine sulfate SR), oxycodone HCl CR, Oxycontin (oxycodone HCl CR).

2. Proposal: Identification of preferred drugs in the therapeutic class Serotonin Receptor Agonists (Triptans).

  • Description: The Committee will review the following drugs to determine preferred and non-preferred status.

    Drugs Affected: Amerge (naratriptan), Axert (almotriptan), Frova (frovatriptan), Imitrex (sumatriptan) tablet/ nasal/injection, Maxalt (rizatriptan) tablet/MLT, Relpax (eletriptan), Zomig (zolmitriptan) tablet/nasal/ZMT.

3. Proposal: Identification of preferred Beta Blocker Combination products in the therapeutic class Beta Blockers.

  • Description: The Committee will review the following drugs to determine preferred and non-preferred status.

    Drugs Affected: atenolol/chlorthalidone, bisoprolol fumarate/HCTZ, Corzide (nadolol/bendroflumethiazide), Inderide (propranolol/HCTZ), Inderide LA (propranolol LA/HCTZ), Lopressor HCT (metoprolol tartrate/HCTZ), metoprolol tartrate/HCTZ, propranolol/HCTZ, Tenoretic (atenolol/chlorthalidone), Timolide (timolol maleate/HCTZ), Ziac (bisoprolol fumarate/HCTZ).

    Note: The Beta Blocker therapeutic class was reviewed during the March 9, 2006 meeting. The Committee will complete the review of this therapeutic class during the May 5, 2006 meeting addressing Beta Blocker Combination products only.

4. Proposal: Identification of preferred drugs in the therapeutic class Sedative Hypnotics.

  • Description: The Committee will review the following drugs to determine preferred and non-preferred status.

    Drugs Affected: Ambien (zolpidem), Ambien CR (zolpidem CR), chloral hydrate, Dalmane (flurazepam), Doral (quazepam), estazolam, flurazepam, Halcion (triazolam), Lunesta (eszopiclone), Prosom (estazolam), Restoril (temazepam), Rozerem (ramelteon), Somnote (chloral hydrate), Sonata (zaleplon), temazepam, triazolam.

5. Proposal: Identification of preferred drugs in the therapeutic class Anti-Emetics.

  • Description: The Committee will review the following drugs to determine preferred and non-preferred status.

    Drugs Affected: Anzemet (dolasetron), Kytril (granisetron) tablet/solution, Zofran (ondansetron) tablet/solution/ODT.

AGENDA

8:45 - 9:00  Welcome and Introductions
9:00 - 10:00  Comments from interested parties*
10:00 - 10:45  Clinical Review of Long Acting Narcotics
10:45 - 11:15  Clinical Review of Serotonin Receptor Agonists (Triptans)
11:15 - 11:30  Clinical Review of Beta Blocker Combination Products (BBCPs)
11:30 - 12:30  Lunch Break/Executive Session (evaluation of trade secret supplemental rebate information)
12:30 - 12:45  Final Recommendations for preferred drugs (Long Acting Narcotics, Triptans and BBCPs)
12:45 - 1:30  Clinical Review of Sedative Hypnotics
1:30 - 2:00  Clinical Review of Anti-Emetics
2:00 - 2:40  Afternoon Break/Executive Session (evaluation of trade secret supplemental rebate information)
2:40 - 2:50  Final Recommendations for preferred drugs (Sedative Hypnotics and Anti-Emetics)
2:50 - 3:00   DOH Update, Final Comments and Adjournment

*Interested parties must notify DOH at least 72 hours in advance of their request to speak at the committee meeting. Requests may be made by calling 518-486-3209 or e-mailing ppno@health.state.ny.us (please reference P&T Committee). Public comments are limited to the specific topics on the agenda, must be brief (2 minutes), and the total comment period will not exceed one (1) hour. Written comments regarding topics before the Committee may also be submitted but must be received at least 72 hours in advance of the meeting. Written comments should summarize key points and may not exceed two pages in length. NOTE: Those wishing to submit clinical information such as a clinical study, a clinical report, or a clinical executive summary, must submit these documents at least two weeks prior to the date of the meeting in order to allow sufficient time for the Committee to review this type of material. If such material is submitted after this time, it cannot be considered by the Committee.

Posted April 4, 2006